Covid: Moderna can take months to ship Omicron-specific vaccine, says CEO

The Omicron variant carries a very high global risk of surges, the WHO warned on Monday

Moderna Covid-19 vaccine
Reuters
1 min read Last Updated : Nov 29 2021 | 7:29 PM IST
Moderna Inc could take months to begin shipping a COVID-19 vaccine that works specifically against the Omicron variant, its chief executive officer, Stéphane Bancel, told CNBC on Monday.
 
The Omicron variant carries a very high global risk of surges, the WHO warned on Monday, as more countries reported cases.
Bancel told CNBC in an interview that the efficacy of COVID-19 vaccines against the variant was currently not known, and that there should be more clarity in about two weeks.
 
Moderna said on Friday it was working to advance a booster candidate tailored to the new variant and has also been testing a higher dose of its existing booster and to study other booster candidates designed to protect against multiple variants.
 
Separately, rivals Pfizer and BioNTech, and Johnson & Johnson have also said they have begun testing their vaccines against the new variant.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story